SENS 401

Drug Profile

SENS 401

Alternative Names: SENS 401

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Sensorion
  • Developer Sensorion; Simbec Research
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sensorineural hearing loss
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Sensorineural hearing loss

Most Recent Events

  • 24 Nov 2016 SENS 401 receives Orphan Drug status for Sensorineural hearing loss in European Union
  • 17 Nov 2016 Pharmacodynamics data from a preclinical trial in Sensorineural hearing loss presented at the Annual Meeting of the Society for Neuroscience (SfN), Neuroscience 2016, CA (SfN-2016)
  • 27 Oct 2016 Phase-I clinical trials in Sensorineural hearing loss (In volunteers) in United Kingdom (PO) (NCT03071003)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top